Abstract 1096
Background
OncotypeDX (ODX®) can enhance prediction of breast cancer recurrence, guiding adjuvant treatment options. However, the opportunity to access this test is not always possible. The aim of this study is to investigate the correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC) and recurrent score (RS) resulting from ODX®.
Methods
All breast cancer patients who underwent ODX® between 2014 and 2018 were retrospectively included in the study. The data selected for analysis were age, menopausal status, pathological and IHC features. IHC was performed with standardized quantitative methods. Dataset was split into two subsets (70% for training and 30% for internal validation). Logistic models were built with statistically significant features for predicting RS ≤ 25 or ≤ 20. An external validation set, provided by another center, was used to test reliability of prediction models.
Results
The internal dataset included 407 patients (Table) who underwent ODX®. Mean age was 53.7 (31-80) and 222 patients (54.55%) were > 50 years old. ODX® results showed: 67 patients (16.6%) between 0-10, 272 patients between 11-25 (66.8%) and 68 pts > 26 (16.6%). At the logistic regression analysis, RS score was significantly associated with ER (p = 0.004), PgR (p < 0.001), and Ki67% (p < 0.001) with the threshold equal to 25. Above patients with RS ≤ 25, the generalized linear regression resulted in a well calibrated model with an AUC of 92.2% (sensitivity 84.2%; specificity 80.1%). External validation set included 180 patients and confirmed the model performance with an AUC of 82.3% and good calibration. A nomogram predicting RS score ≤25 was generated.Table:
261P Tumor characteristics training set + internal test set
Training + internal test set – Tumor characteristics | ||
---|---|---|
Histological subtype classification | Invasive Ductal Carcinoma | 318 pts (78,1%) |
Invasive Lobular Carcinoma | 47 pts (11,5%) | |
Other | 42 pts (10,3%) | |
Grading | 1 | 28 pts (6.8%) |
2 | 268 pts (65,8%) | |
3 | 111 pts (27,3%) | |
pT | 1a | 3 pts (0,7%) |
1b | 38 pts (9,3%) | |
1c | 216 pts (53,1%) | |
2 | 143 pts (35,1%) | |
3 | 6 pts (1,5%) | |
4 | 1 pt (0,3%) | |
pN | 0 | 233 pts (57,2%) |
0i+ | 12 pts (3%) | |
1mic | 43 pts (10,6%) | |
1 | 108 pts (26,5%) | |
NA | 11 pts (2,7%) | |
Mean T diameter [cm] | 1.9 (Range 0,2-8,5) | |
Mean Sentinel Lymph Node (SLN) diameter [mm] | 1.7 (Range 0-40) | |
Mean Axillary Lymph Node (ALN) diameter [mm] | 0.8 (Range 0-25) | |
Mean N Ratio | 0.14 (0.00 – 1.00) | |
SLN involvement [n° of nodes] | 0 | 261 pts (64,1%) |
1 | 112 pts (27,5%) | |
2 | 24 pts (5,8%) | |
3 | 1 pt (0,2%) | |
NA | 9 pts (2,2%) | |
ALN involvement [n° of nodes] | 0 | 338 pts (83%) |
0i+ | 4 pts (1%) | |
1mic | 3 pts (0,7%) | |
1 | 31 pts (7,6%) | |
2 | 8 pts (2%) | |
3 | 5 pts (1,2%) | |
5 | 1 pt (0,2%) | |
NA | 17 pts (4,1%) | |
Multifocality | Yes | 97 pts (23,8%) |
No | 300 pts (73,7%) | |
NA | 10 pts (2.5%) | |
Multicentricity | Yes | 20 pts (4,9%) |
No | 376 pts (92,4%) | |
NA | 11 pts (2,7%) | |
PVI | Absent | 242 pts (59,4%) |
Focal | 51 pts (12,5%) | |
Moderate | 32 pts (7,8%) | |
Massive | 59 pts (14,5%) | |
NA | 23 pts (5,6%) | |
Mean ER expression | 87,9% (Range 1-100) | |
Mean PgR expression | 62.2% (Range 0-100) | |
Mean AR expression | 7.7% (Range 0-90) | |
Mean Ki67% expression | 29.8% (Range 0-90) | |
Her2 Expression | 0 | 187 pts (46%) |
1 | 112 pts (27,5%) | |
2 | 104 pts (25,5%) | |
NA | 4 pts (0,9%) | |
Fluorescence in situ hybridization (FISH) for HER-2 | Not determined | 300 pts (73,7%) |
Not amplificated | 100 pts (23,7%) | |
Undetermined | 1 pt (0,2%) | |
Equivocal | 1 pt (0,2%) |
Conclusions
Quantitative IHC presents a good correlation with RS score in patients with RS ≤ 25, also in external validation set. A nomogram for physician that enhances a cost/effectiveness clinical approach practice has been developed. Prospective clinical application will be tested in further studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabio Marazzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract